The latest biotech news

lupus autoimmune disease neutrophil citryll

News and Trends 22 Jul 2022

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

London-based Freeline Therapeutics Holdings plc has just announced that positive data on treating haemophilia has been published by the New England Journal of Medicine (NEJM). This expands upon previous data for up to three-and-a-half years from the phase 1/2 dose-finding B-AMAZE of the company’s AAVS3 gene therapy candidate, FLT180a for people with the debilitating, hereditary […]

July 22, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes

Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […]

July 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

Australia looks to biotech alliance

The Australian government’s Defence department has announced the launch of the Safeguarding Australia through Biotechnology Response and Engagement alliance (SABRE) at the inaugural Australian Defence Science Technology and Research Summit (ADSTAR) The department said SABRE offers opportunities by bringing together different perspectives of biotech from Australia’s universities, research institutes and small medium enterprises (SME) and […]

July 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Jul 2022

Astellas to create new biotech campus in South San Francisco

Astellas Pharma Inc. has unveiled plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-square-foot building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the San Francisco area. The new innovation […]

July 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Jul 2022

Stroke drug given priority medicine status by European Medicines Agency

A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […]

July 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […]

July 22, 2022

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 22 Jul 2022

Consortium awarded €4M towards platform for personalized cell therapies

A company developing precision T cell therapies that treat solid tumors announced yesterday (July 21) it is leading a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe. The new consortium is being led by Achilles Therapeutics plc and includes CGT Catapult, Leibniz University Hannover (Hannover) as project coordinator, and […]

July 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Poolbeg Pharma gets approval for severe influenza drug trial

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza. Clinical trial activities will formally commence on […]

July 21, 2022 - 4 minutesmins - By Jim Cornall

coronavirus COVID 19 Europe biotech lungs

News and Trends 21 Jul 2022

Additional funding for trial to study drug targeting lung immunity in elderly patients

Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […]

July 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

U.S. biopharma company ZyVersa Therapeutics, Inc., and Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, have entered into a definitive business combination agreement. The transaction is expected to provide ZyVersa with access to the public equity market, which the parties believe will escalate development of ZyVersa’s renal and inflammasome product candidate pipelines. Upon […]

July 21, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

People with hemophilia B could be protected from bleeding by a single dose of a drug currently being trialed

InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes

Australia looks to biotech alliance

Astellas to create new biotech campus in South San Francisco

Stroke drug given priority medicine status by European Medicines Agency

Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma

Consortium awarded €4M towards platform for personalized cell therapies

Poolbeg Pharma gets approval for severe influenza drug trial

Additional funding for trial to study drug targeting lung immunity in elderly patients

Almirall launches new call to find innovative therapies for skin diseases

ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!